DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Laninamivir
Laninamivir
Dectova, INN-Zanamivir
Efficacy of Baloxavir Marboxil on Household Transmission Of
Summary of Neuraminidase Amino Acid Substitutions Associated with Reduced Inhibition by Neuraminidase Inhibitors
Comprehensive Analysis of Drugs to Treat SARS‑Cov‑2 Infection: Mechanistic Insights Into Current COVID‑19 Therapies (Review)
Clinical Review Melisse Baylor, MD NDA 210854 Baloxavir Marboxil
A Computational Approach to Aid Clinicians in Selecting Anti-Viral
Clinical Efficacy of New Neuraminidase Inhibitors, Laninamivir And
Combined Therapy of Influenza with Antiviral Drugs with a Different Mechanism of Action in Comparison with Monotherapy
Clinical Implications of Antiviral Resistance in Influenza
Incomplete Inhalation of Laninamivir Octanoate in Children with Influenza
In Vitro Combinations of Baloxavir Acid and Other Inhibitors Against Seasonal Influenza a Viruses
210854Orig1s000
Approved Antiviral Drugs Over the Past 50 Years
Study Protocol
Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives
Xofluza, INN-Baloxavir Marboxil
Favipiravir (JAN*) [Applicant] Toyama Chemical Co., Ltd
Antivirals Targeting the Surface Glycoproteins of Influenza Virus
Top View
Report on the Deliberation Results November 26, 2013 Evaluation And
Review Laninamivir and Its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
Expert Opinion on Neuraminidase Inhibitors for the Prevention and Treatment of Influenza
Inhaled Laninamivir Octanoate As Prophylaxis for Influenza in Children
Can Antiviral Drugs Known Today Are Useful in the Treatment of Novel Corona Virus Or COVID-19?
Remdesivir from Wikipedia, the Free Encyclopedia
Pharmacokinetics of Laninamivir After a Single Administration of Its
Antiviral Drugs – Aspects of Clinical Use and Recent Advances
Joji Nakayama, Representative Director, Pres
Peramivir and Laninamivir Susceptibility of Circulating Influenza
Program and Abstracts International Conference Antiviral Research
Clinical Use of Approved Influenza Antivirals
New Treatment Strategies for Influenza Luis Del Carpio-Orantes*
Antiviral Treatments
Report on the Deliberation Results August 3, 2010 Evaluation And